Skip to main content

Advertisement

SpringerLink
Log in

Neurological toxicities of targeted therapies in melanoma: a multicenter national observational study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC)

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

  • 1 Altmetric

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Heinzerling L, Eigentler TK, Fluck M et al (2019) Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open 4(3):e000491. https://doi.org/10.1136/esmoopen-2019-000491

    Article  PubMed  PubMed Central  Google Scholar 

  2. Meirson T, Asher N, Bomze D et al (2020) Safety of BRAF+MEK inhibitor combinations: severe adverse event evaluation. Cancers (Basel) 12(6):E1650. https://doi.org/10.3390/cancers12061650

    Article  CAS  Google Scholar 

  3. Sunandana C, Jacob SC, Jeffrey AS (2023) Melanoma: does sequencing really matter? J Clin Oncol 41(2):167–169. https://doi.org/10.1200/JCO.22.01354

    Article  Google Scholar 

  4. Douglas BJ, Ali M, Alexandra MH et al (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer 7(1):134. https://doi.org/10.1186/s40425-019-0617-x

    Article  Google Scholar 

  5. Muhammad ZF, Sheeba BA, Prasanth L (2022) Association of immune checkpoint inhibitors with neurologic adverse events: a systematic review and meta-analysis. JAMA Netw Open 5(4):e227722. https://doi.org/10.1001/jamanetworkopen.2022.7722

    Article  Google Scholar 

  6. Picca A, Birzu C, Berzero G (2022) Peripheral neuropathies after BRAF and/or MEK inhibitor treatment: a pharmacovigilance study. Br J Clin Pharmacol 88(11):4941–4949. https://doi.org/10.1111/bcp.15513

    Article  CAS  PubMed  Google Scholar 

  7. Velter C, Libenciuc C, Routier E et al (2019) Neurotoxicity induced by targeted therapies in patients treated for metastatic melanoma. Eur J Cancer 111:8–11. https://doi.org/10.1016/j.ejca.2019.01.017

    Article  CAS  PubMed  Google Scholar 

  8. Eggermont AMM, Robert C, Ribas A (2018) The new era of adjuvant therapies for melanoma. Nat Rev Clin Oncol 15(9):535–536. https://doi.org/10.1038/s41571-018-0048-5

    Article  CAS  PubMed  Google Scholar 

  9. Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V et al (2022) Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet 399(10336):1718–1729. https://doi.org/10.1016/S0140-6736(22)00562-1

    Article  CAS  PubMed  Google Scholar 

  10. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR et al (2013) BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 19(5):1225–1231. https://doi.org/10.1158/1078-0432.CCR-12-1630

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CNJ, Sloss CM et al (2010) Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70(13):5213–5219. https://doi.org/10.1158/0008-5472.CAN-10-0118

    Article  CAS  PubMed  Google Scholar 

  12. Baroffio A, Dupin E, Le Douarin NM (1991) Common precursors for neural and mesectodermal derivatives in the cephalic neural crest. Development 112(1):301–305. https://doi.org/10.1242/dev.112.1.301

    Article  CAS  PubMed  Google Scholar 

  13. Harrisingh MC, Perez-Nadales E, Parkinson DB, Malcolm DS, Mudge AW, Lloyd AC (2004) The Ras/Raf/ERK signalling pathway drives Schwann cell dedifferentiation. EMBO J 23(15):3061–3071

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This article has no funding source.

Author information

Authors and Affiliations

  1. Department of Dermatology, Hospital Dupuytren 2, UHC of Limoges, Limoges, France

    Madeleine Hazard

  2. Department of Medical Neurology, Hospital Pellegrin, UHC of Bordeaux, Bordeaux, France

    Fanny Duval

  3. Department of Dermatology, Hôpital Saint-André, CHU de Bordeaux, Bordeaux, France

    Caroline Dutriaux, Marie Beylot-Barry, Anne Pham-Ledard, Sorilla Prey & Emilie Gérard

  4. BRIC (Bordeaux Institute of Oncology), UMR1312, INSERM, Univ. Bordeaux, 33000, Bordeaux, France

    Caroline Dutriaux, Marie Beylot-Barry, Anne Pham-Ledard, Sorilla Prey & Emilie Gérard

  5. Department of Dermatology, UHC of Nantes, France, CIC 1413, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, 44000, Nantes, France

    Gaelle Quereux, Amir Khammari & Brigitte Dréno

  6. Department of Dermatology, UHC of Lyon, Lyon, France

    Mona Amini-Adle

  7. Department of Dermatology, Hospital Avicenne, AP-HP, Paris, France

    Valentine Heidelberger

  8. Department of Dermatology, UHC of Besançon, Besançon, France

    François Aubin & Charlée Nardin

  9. Department of Oncology, Cancer Comprehensive Center, Saint-Herblain, France

    Mélanie Saint-Jean

  10. Department of Dermatology, Military Training Hospital of Sainte Anne, Toulon, France

    Safia Abed

  11. Department of Dermatology, UHC of Grenoble, Grenoble, France

    Marie-Thérèse Leccia

  12. Department of Dermatology, Estaing Hospital, Clermont-Ferrand, France

    Sandrine Mansard

Authors
  1. Madeleine Hazard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fanny Duval
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Caroline Dutriaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marie Beylot-Barry
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anne Pham-Ledard
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gaelle Quereux
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mona Amini-Adle
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Valentine Heidelberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. François Aubin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mélanie Saint-Jean
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Charlée Nardin
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Safia Abed
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Marie-Thérèse Leccia
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Sandrine Mansard
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Sorilla Prey
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Amir Khammari
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Brigitte Dréno
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Emilie Gérard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emilie Gérard.

Ethics declarations

Conflicts of interest

The authors have no financial interests in this article. EG: congress fees and investigator for Novartis and Pierre Fabre Dermatology. FD, MBB, APL, VH, MSJ, SA, MTL, AK, and BD have no conflict of interest. CD: congress fees, consulting, boards and investigation on trials for Novartis and Pierre Fabre Oncology. GQ: congress fees, investigator, board member, or consultant for BMS, Regeneron, MSD, Pfizer, Novartis, Pierre Fabre oncology and Sanofi. MA: has received fees from BMS, Pierre Fabre oncology, Sanofi and Sun Pharma for advisory board, financial support for congress participation. FA is board member or consultant or received payment for development of educational presentations and including travel/accommodations expenses covered or reimbursed from Abbvie, Amgen, Almirall, MSD, BMS, Pfizer, Abbott, Janssen-Cilag, Galderma, Leo Pharma, Medac, Galderma, Kiowa Kirin Pharma, UCB, Novartis, Sanofi, Takeda, La Roche Posay, Sun Pharma, Uriage, Viatris. ChN is a consultant or member of advisory boards with BMS, MSD and Novartis and has received financial support for travel and accommodation expenses from BMS, MSD and Novartis. SM: Pierre Fabre et novartis, advisory Board and congress fees. SP: congress fees and investigator for Novartis and Pierre Fabre Dermatology.

Ethical standard statement

This study adheres to the ethical standards outlined in the Declaration of Helsinki. The research protocol was approved by the institutional review board, and all participants provided informed consent. Confidentiality and privacy of the subjects were maintained throughout the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hazard, M., Duval, F., Dutriaux, C. et al. Neurological toxicities of targeted therapies in melanoma: a multicenter national observational study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC). J Neurol 271, 1473–1482 (2024). https://doi.org/10.1007/s00415-023-12105-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-023-12105-2

Search

Navigation